On January 29, 2024 Vesicure Therapeutics reported its SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene (Press release, Vesicure Therapeutics, JAN 29, 2024, View Source [SID1234639674]). This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic disorders. In the US, five siRNA-based drugs have been approved, with several candidates undergoing clinical trials for conditions like COVID-19, HBV, cancer, and diabetes.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Despite promising capabilities, siRNA drugs require efficient and safe delivery systems, as bloodstream clearance and limited tissue penetration beyond the liver remain as major challenges. Vesicure Therapeutics, a biotech company from Suzhou China, recently introduced their exosome-based siRNA delivery platform in a proof-of-concept study, by efficiently shuttling cell survival siRNA cargo to inhibit tumor growth through intratumoral (it) injection (BioRxiv: doi: View Source).
Taking a significant stride forward, in a new study, Vesicure extended the feasibility of this exosome-siRNA technology in targeting KRAS mutation in a CDX (Cell line-derived xenograft) mouse model (BioRxiv: doi: View Source). The data revealed that intravenously (iv) injected exosomes were enriched in tumors. These ‘KRAS siRNA carriers’ exhibited excellent tumor retention and growth inhibition without significant toxicity to mice. This advancement marks progress in developing exosomes for extrahepatic siRNA drug delivery for targeting previously deemed undruggable targets to address unmet therapeutic needs.
Media Enquiry
[email protected]
View Source